RightFit Trial Directory

Lung Cancer clinical trials in Portland, OR

33 recruiting lung cancer studies with a site in Portland, OR.

All trials in Portland, OR · All Lung Cancer trials

RecruitingPhase 3NCT03394365

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Sponsor: Pierre Fabre Medicament

Portland, OR · +39 more sites

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Baker City, OR · Bend, OR · Clackamas, OR · +1147 more sites

RecruitingPhase 3NCT06498635

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Sponsor: National Cancer Institute (NCI)

Hood River, OR · Newberg, OR · Oregon City, OR · +278 more sites

RecruitingPhase 3NCT07144280

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Sponsor: Pfizer

Beaverton, OR · Eugene, OR · Gresham, OR · +238 more sites

RecruitingPhase 4NCT07405086

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Sponsor: OHSU Knight Cancer Institute

Portland, OR

RecruitingPhase 2NCT06031688

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Newberg, OR · Ontario, OR · Oregon City, OR · +275 more sites

RecruitingPhase 2 / Phase 3NCT07100080

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Sponsor: Bristol-Myers Squibb

Portland, OR · +25 more sites

RecruitingPhase 3NCT07222566

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor: Pfizer

Happy Valley, OR · Portland, OR · Tigard, OR · +223 more sites

RecruitingPhase 1 / Phase 2NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Sponsor: Genmab

Eugene, OR · Portland, OR · +35 more sites

RecruitingPhase 3NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Eugene, OR · Medford, OR · Portland, OR · +84 more sites

RecruitingPhase 1 / Phase 2NCT06780137

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Sponsor: Merck Sharp & Dohme LLC

Portland, OR · +8 more sites

RecruitingPhase 1 / Phase 2NCT05797168

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Sponsor: AstraZeneca

Portland, OR · +12 more sites

RecruitingPhase 2NCT07293247

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Sponsor: Alliance for Clinical Trials in Oncology

Clackamas, OR · Newberg, OR · Oregon City, OR · +108 more sites

RecruitingPhase 1NCT07814248

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

Sponsor: TwoStep Therapeutics, Inc.

Portland, OR · +2 more sites

RecruitingPhase 1NCT05877599

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Sponsor: AstraZeneca

Portland, OR · +19 more sites

RecruitingPhase 1NCT06218914

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Sponsor: AstraZeneca

Portland, OR · +17 more sites

RecruitingPhase 3NCT06357533

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Sponsor: AstraZeneca

Portland, OR · +62 more sites

RecruitingPhase 2 / Phase 3NCT07063745

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Sponsor: Bristol-Myers Squibb

Portland, OR · +42 more sites

RecruitingPhase 3NCT06767514

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Sponsor: Summit Therapeutics

Eugene, OR · Portland, OR · +95 more sites

RecruitingPhase 2NCT06855771

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Sponsor: Bristol-Myers Squibb

Portland, OR · +8 more sites

RecruitingPhase 1NCT07080242

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Sponsor: SystImmune Inc.

Portland, OR · +23 more sites

RecruitingPhase 1 / Phase 2NCT04895709

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Sponsor: Bristol-Myers Squibb

Portland, OR · +10 more sites

RecruitingPhase 1NCT06242470

A Study of MGC026 in Participants With Advanced Solid Tumors

Sponsor: MacroGenics

Portland, OR · +6 more sites

RecruitingPhase 3NCT06203210

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Sponsor: Daiichi Sankyo

Portland, OR · +29 more sites

RecruitingPhase 1 / Phase 2NCT05098132

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Sponsor: Synthekine

Portland, OR · +32 more sites

RecruitingPhase 2NCT05705492

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

Sponsor: OHSU Knight Cancer Institute

Portland, OR

RecruitingPhase 1NCT04389632

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Portland, OR · +103 more sites

RecruitingPhase 2NCT05642572

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Newberg, OR · Ontario, OR · Oregon City, OR · +451 more sites

RecruitingPhase 2 / Phase 3NCT03851445

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

Sponsor: SWOG Cancer Research Network

Baker City, OR · Bend, OR · Clackamas, OR · +1226 more sites

RecruitingPhase 3NCT02468024

JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

Sponsor: University of Texas Southwestern Medical Center

Portland, OR · +39 more sites

RecruitingPhase 2NCT06769126

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Sponsor: SWOG Cancer Research Network

Newberg, OR · Oregon City, OR · Portland, OR · +145 more sites

RecruitingPhase 1NCT06805825

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Sponsor: Novelty Nobility, Inc.

Portland, OR · +4 more sites

Not yet recruitingPhase 2NCT07871214

A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

Sponsor: Bristol-Myers Squibb

Portland, OR · +8 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.